<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04014023</url>
  </required_header>
  <id_info>
    <org_study_id>DWP16001201</org_study_id>
    <nct_id>NCT04014023</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of DWP16001 compared to
      placebo in the treatment of type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>at 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG</measure>
    <time_frame>at week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who achieve HbA1c &lt; 7.0%, HbA1c &lt; 6.5% and HbA1c reduction &gt;0.5% from baseline</measure>
    <time_frame>at week 4, 8, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>T2DM (Type 2 Diabetes Mellitus)</condition>
  <arm_group>
    <arm_group_label>DWP16001 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Amg, Tablets, Orally, Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP16001 Bmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Bmg, Tablets, Orally, Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWP16001 Cmg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP16001 Cmg, Tablets, Orally, Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, Tablets, Orally, Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP16001</intervention_name>
    <description>DWP16001 tablets</description>
    <arm_group_label>DWP16001 Amg</arm_group_label>
    <arm_group_label>DWP16001 Bmg</arm_group_label>
    <arm_group_label>DWP16001 Cmg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>DWP16001 placebo-matching tablets</description>
    <arm_group_label>DWP16001 Amg</arm_group_label>
    <arm_group_label>DWP16001 Bmg</arm_group_label>
    <arm_group_label>DWP16001 Cmg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 20 to 80 years

          -  Patients who was diagnosed with type 2 diabetes mellitus at least 8 weeks before

          -  Body Mass Index (BMI) between 20 and 45 kg/㎡

          -  Patients with 7% ≤ HbA1c ≤ 10% at screening

          -  Subject who has conducted a stable diet and exercise for at least 8 weeks

        Exclusion Criteria:

          -  Type 1 diabetes mellitus or secondary diabetes

          -  Severe diabetes complications (proliferative diabetic retinopathy, stage 4 or higher
             nephropathy or severe diabetic neuropathy, diabetic ketoacidosis)

          -  Clinical significantly renal disorders

          -  Creatinine clearance &lt; 60ml/min (0.84ml/s/㎡) or Glomerular filtration rate(eGFR) &lt;
             60mL/min/1.73

          -  Severe gastrointestinal disorder

          -  Uncontrolled hypertension (SBP &gt;180 mmHg or DBP &gt; 110 mmHg)

          -  History of Acute coronary syndrome, unstable angina, myocardial infarction requiring
             hospitalization, stroke, transient ischemic attack, severe heart failure (NYHA class
             III/IV), or heart arrhythmia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Choi</last_name>
    <email>jhchoi413@daewoong.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyun</last_name>
    <email>wrhyun075@daewoong.co.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Daewoong pharmatceutical</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 7, 2019</study_first_submitted>
  <study_first_submitted_qc>July 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

